AstroRx

Kadimastem is planning a Phase 2a clinical trial to test if repeat dosing of AstroRx, its investigational therapy for amyotrophic lateral sclerosis (ALS), can continuously delay the disease’s progression. The study will investigate every three-month dosing after findings from an earlier Phase 1/2 trial (NCT03482050) showed a…

Kadimastem’s experimental cell-based therapy AstroRx was safe and significantly slowed disease progression in the first three months among people with amyotrophic lateral sclerosis (ALS), a Phase 1/2 clinical study shows. The findings are in line with initial data released by the company in 2020, with AstroRx more…

Kadimastem has received a U.S. patent covering its investigational cell therapy AstroRx for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The patent, granted by the U.S. Patent and Trademark Office, supports an upcoming Phase 2a clinical trial that’s planned to start in the U.S. next year.

A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according to updated data from an ongoing Phase 1/2 trial. These benefits waned after six months, indicating…

Kadimastem’s cell therapy candidate, AstroRx, significantly lowers the rate of disease progression in people with amyotrophic lateral sclerosis (ALS) for at least three months after treatment, updated findings from the company’s Phase 1/2 clinical trial show. The company already had reported promising…

Amyotrophic lateral sclerosis (ALS) patients receiving the lowest dose of Kadimastem’s cell therapy candidate, AstroRx, experienced a significant reduction in disease progression in the three or four months after treatment, updated findings from the company’s Phase 1/2 clinical trial show. In subsequent…

Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing the safety and preliminary efficacy of AstroRx, an investigational stem cell therapy for amyotrophic lateral sclerosis (ALS). AstroRx is an off-the-shelf cell therapy consisting…

ALS News Today brought you daily coverage of key findings, treatment developments, clinical trials, and other important events related to amyotrophic lateral sclerosis (ALS) throughout 2020, a year marked by the COVID-19 pandemic. As a…

Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an “off-the-shelf” stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS). The company wants to change the planned dosage in one of the…

Kadimastem’s experimental cell therapy — AstroRx — may slow disease progression in patients with amyotrophic lateral sclerosis (ALS), according to interim results in a first group of patients treated in a Phase 1/2a study. AstroRx consists of functional healthy astrocytes — cells that support and protect neurons…